Skip to main content
European Commission logo print header

Sustained Release Ocular Bevacizumab for the treatment of wet acute macular degeneration

Ziel

Sustained Release Ocular Bevacizumab for the treatment of wet acute macular degeneration

This feasibility study is to verify the technical and economic viability of a sustained release bevacizumab product (SR Bevacizumab) to improve the safety, cost-effectiveness and patient acceptability for the treatment of wet age-related macular degeneration (AMD). AMD is the leading cause of blindness in those aged over 50 and causes blurring, distortion and loss of central vision and almost always affects quality of life. Prototype SR Bevacizumab products will be manufactured using CriticalMix, an advanced manufacturing and processing technology developed by Critical Pharmaceuticals, which will encapsulate bevacizumab in biodegradable polymers suitable for sustained release of the drug in the eye.

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2014-2015

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-1-2014

Koordinator

CRITICAL PHARMACEUTICALS LIMITED
Netto-EU-Beitrag
€ 50 000,00
Adresse
BIOCITY NOTTINGHAM - PENNYFOOT STREET
NG1 1GF NOTTINGHAM
Vereinigtes Königreich

Auf der Karte ansehen

KMU

Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen).

Ja
Region
East Midlands (England) Derbyshire and Nottinghamshire Nottingham
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Gesamtkosten
€ 71 429,00